ImmuPharma (LON:IMM) Shares Down 13.1% - Here's Why

Key Points

• ImmuPharma shares fell by 13.1%, trading as low as GBX 11.15 ($0.15) before last trading at GBX 12.95 ($0.18) amidst increased trading volume of 25.3 million shares.
• The company reported a net margin of 3,519.56% and a negative return on equity of 131.41% during its last earnings report, while analysts predict EPS of -339.00 for the current fiscal year.
• ImmuPharma is a specialty biopharmaceutical company focused on peptide-based therapeutics, with its lead program being Lupuzor™, aimed at treating autoimmune diseases like Lupus.

Shares of ImmuPharma plc (LON:IMM - Get Free Report) traded down 13.1% during mid-day trading on Wednesday . The company traded as low as GBX 11.15 ($0.15) and last traded at GBX 12.95 ($0.17). 25,266,654 shares were traded during trading, an increase of 200% from the average session volume of 8,415,675 shares. The stock had previously closed at GBX 14.90 ($0.20).

ImmuPharma Price Performance

The stock's fifty day moving average price is GBX 4.28 and its 200-day moving average price is GBX 3.27. The firm has a market cap of £62.47 million, a price-to-earnings ratio of -1,404.49 and a beta of 1.53.

ImmuPharma (LON:IMM - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share (EPS) for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. As a group, equities research analysts predict that ImmuPharma plc will post -339.0000022 EPS for the current fiscal year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.